JP2022550915A5 - - Google Patents

Info

Publication number
JP2022550915A5
JP2022550915A5 JP2022520976A JP2022520976A JP2022550915A5 JP 2022550915 A5 JP2022550915 A5 JP 2022550915A5 JP 2022520976 A JP2022520976 A JP 2022520976A JP 2022520976 A JP2022520976 A JP 2022520976A JP 2022550915 A5 JP2022550915 A5 JP 2022550915A5
Authority
JP
Japan
Prior art keywords
composition according
oligonucleotides
c9orf72
pharmaceutical composition
repeat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022520976A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022550915A (ja
Filing date
Publication date
Priority claimed from PCT/US2020/032244 external-priority patent/WO2020227691A2/en
Application filed filed Critical
Priority claimed from PCT/US2020/054307 external-priority patent/WO2021071788A2/en
Publication of JP2022550915A publication Critical patent/JP2022550915A/ja
Publication of JP2022550915A5 publication Critical patent/JP2022550915A5/ja
Priority to JP2025133056A priority Critical patent/JP2025179843A/ja
Pending legal-status Critical Current

Links

JP2022520976A 2019-10-06 2020-10-05 オリゴヌクレオチド組成物及びその使用方法 Pending JP2022550915A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025133056A JP2025179843A (ja) 2019-10-06 2025-08-08 オリゴヌクレオチド組成物及びその使用方法

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962911340P 2019-10-06 2019-10-06
US62/911,340 2019-10-06
US202062983736P 2020-03-01 2020-03-01
US62/983,736 2020-03-01
USPCT/US2020/032244 2020-05-08
PCT/US2020/032244 WO2020227691A2 (en) 2019-05-09 2020-05-08 Oligonucleotide compositions and methods of use thereof
US202063069704P 2020-08-24 2020-08-24
US63/069,704 2020-08-24
PCT/US2020/054307 WO2021071788A2 (en) 2019-10-06 2020-10-05 Oligonucleotide compositions and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025133056A Division JP2025179843A (ja) 2019-10-06 2025-08-08 オリゴヌクレオチド組成物及びその使用方法

Publications (2)

Publication Number Publication Date
JP2022550915A JP2022550915A (ja) 2022-12-05
JP2022550915A5 true JP2022550915A5 (cg-RX-API-DMAC7.html) 2024-01-11

Family

ID=75438309

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022520976A Pending JP2022550915A (ja) 2019-10-06 2020-10-05 オリゴヌクレオチド組成物及びその使用方法
JP2025133056A Pending JP2025179843A (ja) 2019-10-06 2025-08-08 オリゴヌクレオチド組成物及びその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025133056A Pending JP2025179843A (ja) 2019-10-06 2025-08-08 オリゴヌクレオチド組成物及びその使用方法

Country Status (12)

Country Link
US (1) US20240175016A1 (cg-RX-API-DMAC7.html)
EP (1) EP4037695A4 (cg-RX-API-DMAC7.html)
JP (2) JP2022550915A (cg-RX-API-DMAC7.html)
KR (1) KR20220070324A (cg-RX-API-DMAC7.html)
CN (1) CN114585370A (cg-RX-API-DMAC7.html)
AU (1) AU2020363344A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022006207A2 (cg-RX-API-DMAC7.html)
CA (1) CA3156176A1 (cg-RX-API-DMAC7.html)
IL (1) IL291974A (cg-RX-API-DMAC7.html)
MX (1) MX2022004102A (cg-RX-API-DMAC7.html)
TW (1) TW202126810A (cg-RX-API-DMAC7.html)
WO (1) WO2021071788A2 (cg-RX-API-DMAC7.html)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2872147T3 (da) 2012-07-13 2023-02-20 Wave Life Sciences Ltd Fremgangsmåde til fremstilling af kirale oligonukleotider
WO2014010250A1 (en) 2012-07-13 2014-01-16 Chiralgen, Ltd. Asymmetric auxiliary group
EP3094728B1 (en) 2014-01-16 2022-03-09 Wave Life Sciences Ltd. Chiral design
AU2015367378A1 (en) 2014-12-17 2017-06-15 Proqr Therapeutics Ii B.V. Targeted RNA editing
CN117965536A (zh) 2015-07-22 2024-05-03 波涛生命科学有限公司 寡核苷酸组合物及其方法
MA46427A (fr) 2015-10-09 2018-08-15 Wave Life Sciences Ltd Compositions d'oligonucléotides et procédés associés
MA43822A (fr) 2016-03-13 2018-11-28 Wave Life Sciences Ltd Compositions et procédés de synthèse de phosphoramidite et d'oligonucléotides
US11013757B2 (en) 2016-06-03 2021-05-25 Wave Life Sciences Ltd. Oligonucleotides, compositions and methods thereof
EP3475424A1 (en) 2016-06-22 2019-05-01 ProQR Therapeutics II B.V. Single-stranded rna-editing oligonucleotides
WO2018041973A1 (en) 2016-09-01 2018-03-08 Proqr Therapeutics Ii B.V. Chemically modified single-stranded rna-editing oligonucleotides
WO2018098264A1 (en) 2016-11-23 2018-05-31 Wave Life Sciences Ltd. Compositions and methods for phosphoramidite and oligonucleotide synthesis
CA3065523A1 (en) 2017-06-02 2018-12-06 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
US11603532B2 (en) 2017-06-02 2023-03-14 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
WO2018237194A1 (en) 2017-06-21 2018-12-27 Wave Life Sciences Ltd. Compounds, compositions and methods for synthesis
AU2018316159A1 (en) 2017-08-08 2020-02-06 Wave Life Sciences Ltd. Oligonucleotide compositions and methods thereof
CN111108096A (zh) 2017-09-18 2020-05-05 波涛生命科学有限公司 寡核苷酸制备技术
EP3694530A4 (en) 2017-10-12 2021-06-30 Wave Life Sciences Ltd. COMPOSITIONS OF OLIGONUCLEOTIDES AND RELATED PROCESSES
JP2021521140A (ja) 2018-04-12 2021-08-26 ウェイブ ライフ サイエンシズ リミテッドWave Life Sciences Ltd. オリゴヌクレオチド組成物及びその使用方法
CA3098624A1 (en) 2018-05-11 2019-11-14 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
GB201808146D0 (en) 2018-05-18 2018-07-11 Proqr Therapeutics Ii Bv Stereospecific Linkages in RNA Editing Oligonucleotides
AU2020241559A1 (en) 2019-03-20 2021-11-11 Wave Life Sciences Ltd. Technologies useful for oligonucleotide preparation
MX2021012981A (es) 2019-04-25 2022-01-18 Wave Life Sciences Ltd Composiciones de oligonucleotido y metodos de uso de las mismas.
EP4479535A1 (en) 2022-02-14 2024-12-25 ProQR Therapeutics II B.V. Guide oligonucleotides for nucleic acid editing in the treatment of hypercholesterolemia
EP4555086A1 (en) 2022-07-15 2025-05-21 ProQR Therapeutics II B.V. Oligonucleotides for adar-mediated rna editing and use thereof
EP4555085A1 (en) 2022-07-15 2025-05-21 ProQR Therapeutics II B.V. Chemically modified oligonucleotides for adar-mediated rna editing
GB202215614D0 (en) 2022-10-21 2022-12-07 Proqr Therapeutics Ii Bv Heteroduplex rna editing oligonucleotide complexes
KR20250113455A (ko) 2022-11-24 2025-07-25 프로큐알 테라퓨틱스 Ⅱ 비.브이. 유전성 hfe-혈색소침착증의 치료를 위한 안티센스 올리고뉴클레오티드
GB202218090D0 (en) 2022-12-01 2023-01-18 Proqr Therapeutics Ii Bv Antisense oligonucleotides for the treatment of aldehyde dehydrogenase 2 deficiency
WO2024121373A1 (en) 2022-12-09 2024-06-13 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of cardiovascular disease
GB202300865D0 (en) 2023-01-20 2023-03-08 Proqr Therapeutics Ii Bv Delivery of oligonucleotides
WO2024175550A1 (en) 2023-02-20 2024-08-29 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of atherosclerotic cardiovascular disease
GB202304363D0 (en) 2023-03-24 2023-05-10 Proqr Therapeutics Ii Bv Chemically modified antisense oligonucleotides for use in RNA editing
JP2026510408A (ja) 2023-03-24 2026-04-02 プロキューアール セラピューティクス ツー ベスローテン フェンノートシャップ 神経障害の処置のためのアンチセンスオリゴヌクレオチド
EP4688143A1 (en) 2023-03-27 2026-02-11 ProQR Therapeutics II B.V. Antisense oligonucleotides for the treatment of liver disease
WO2024256620A1 (en) 2023-06-16 2024-12-19 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of neurodegenerative disease
EP4774393A1 (en) 2023-09-07 2026-07-15 ProQR Therapeutics II B.V. Antisense oligonucleotides for the treatment of metabolic disorders
AU2024379264A1 (en) 2023-11-16 2026-05-14 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of classic galactosemia
AU2024402199A1 (en) 2023-12-20 2026-07-16 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of huntington's disease
GB202404661D0 (en) 2024-04-02 2024-05-15 Proqr Therapeutics Ii Bv Antisense oligoncleotides for the treatment of liver disease
WO2025224230A1 (en) 2024-04-25 2025-10-30 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of fatty liver disease
GB202410081D0 (en) 2024-07-11 2024-08-28 Proqr Therapeutics Ii Bv Antisense oligonucleotides for the treatment of cardiovascular disease
WO2026022136A1 (en) 2024-07-23 2026-01-29 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of metabolic disorders
WO2026060374A2 (en) 2024-09-16 2026-03-19 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of neurological disorders
WO2026068781A1 (en) 2024-09-30 2026-04-02 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of liver disease
WO2026093339A1 (en) 2024-10-29 2026-05-07 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of peroxisome biogenesis disorders in the zellweger spectrum (pbd-zsd)
WO2026136663A1 (en) 2024-12-18 2026-06-25 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of neurodegenerative disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6756700B2 (ja) * 2014-03-18 2020-09-16 ユニバーシティ オブ マサチューセッツ 筋萎縮性側索硬化症を処置するためのrAAVベースの組成物および方法
RU2708237C2 (ru) * 2014-08-22 2019-12-05 Общество с ограниченной ответственностью "НооГен" Модифицированные олигонуклеотиды и способ их получения
WO2016168592A2 (en) * 2015-04-16 2016-10-20 Ionis Pharmaceuticals, Inc. Compositions for modulating c9orf72 expression
MA46427A (fr) * 2015-10-09 2018-08-15 Wave Life Sciences Ltd Compositions d'oligonucléotides et procédés associés
WO2017079291A1 (en) * 2015-11-02 2017-05-11 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating c90rf72
AU2018316159A1 (en) * 2017-08-08 2020-02-06 Wave Life Sciences Ltd. Oligonucleotide compositions and methods thereof
EP3965780A4 (en) * 2019-05-09 2023-10-25 Wave Life Sciences Ltd. OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE

Similar Documents

Publication Publication Date Title
JP2022532169A5 (cg-RX-API-DMAC7.html)
JP2020534253A5 (cg-RX-API-DMAC7.html)
JP2025165976A5 (cg-RX-API-DMAC7.html)
JP2024009824A5 (cg-RX-API-DMAC7.html)
JP2021522803A5 (cg-RX-API-DMAC7.html)
JP2023145620A5 (cg-RX-API-DMAC7.html)
US20220098585A1 (en) Oligonucleotide compositions and methods thereof
JP2009532392A5 (cg-RX-API-DMAC7.html)
CA3156176A1 (en) Oligonucleotide compositions and methods of use thereof
JP2021512629A5 (cg-RX-API-DMAC7.html)
JP2025041652A5 (cg-RX-API-DMAC7.html)
CA3139513A1 (en) Oligonucleotide compositions and methods of use thereof
JP2018525357A5 (cg-RX-API-DMAC7.html)
JP2022551124A5 (cg-RX-API-DMAC7.html)
JP2020522265A5 (cg-RX-API-DMAC7.html)
JP2021007391A5 (cg-RX-API-DMAC7.html)
JP2018513682A5 (cg-RX-API-DMAC7.html)
JP2022517783A (ja) 活性剤の脂質ナノ粒子送達のための脂質
CA3137740A1 (en) Oligonucleotide compositions and methods of use thereof
JP2016513976A5 (cg-RX-API-DMAC7.html)
JP2024536088A5 (cg-RX-API-DMAC7.html)
JP2015502365A5 (cg-RX-API-DMAC7.html)
JP2014527401A5 (cg-RX-API-DMAC7.html)
JP2015511494A5 (cg-RX-API-DMAC7.html)
WO1995017507A1 (en) ANTISENSE NUCLEIC ACIDS FOR THE PREVENTION AND TREATMENT OF DISORDERS IN WHICH EXPRESSION OF c-erbB PLAYS A ROLE